Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01722526 · ClinicalTrials.gov registry record · Phase 1
Tolerability and Safety Study of Recombinant Human Acid Sphingomyelinase in Acid Sphingomyelinase Deficiency Patients
A Phase 1 study of Human Acid Sphingomyelinase Deficiency, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 2
- Study locations
NCT01722526 is a Phase 1 study of Human Acid Sphingomyelinase Deficiency that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 5 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT01722526, a Phase 1 study of Human Acid Sphingomyelinase Deficiency, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 2
- Study locations
Study Summary
To evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic profile of rhASM in adult patients with Acid Sphingomyelinase Deficiency (ASMD) following repeated-dose administration.
Conditions Studied
Interventions
- DRUG Recombinant human acid sphingomyelinase
Study Locations (2)
New York
- Mount Sinai School of Medicine - New York
Other
- St. Mary's Hospital - Manchester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2013-03 |
| Est. Completion | 2014-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01722526
The ClinicalTrials.gov registry entry for NCT01722526 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Human Acid Sphingomyelinase Deficiency appearing as the primary indexed condition, and to 1 intervention - of which Recombinant human acid sphingomyelinase is the first listed.
NCT01722526 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New York, Other.
Frequently Asked Questions
What is clinical trial NCT01722526 about?
NCT01722526 is a clinical study titled "Tolerability and Safety Study of Recombinant Human Acid Sphingomyelinase in Acid Sphingomyelinase Deficiency Patients". To evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic profile of rhASM in adult patients with Acid Sphingomyelinase Deficiency (ASMD) following repeated-dose administration.
What is the current status of trial NCT01722526?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2013-03. Estimated completion is 2014-01.
What conditions does trial NCT01722526 study?
This clinical trial studies the following conditions: Human Acid Sphingomyelinase Deficiency.
What interventions are being tested in trial NCT01722526?
The interventions under investigation include: Recombinant human acid sphingomyelinase (DRUG).
Who is sponsoring clinical trial NCT01722526?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01722526 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.